Efficacy of whole system ayurveda management protocol in major depressive disorder- A randomized controlled clinical trial

IF 1.9 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE Journal of Ayurveda and Integrative Medicine Pub Date : 2024-03-01 DOI:10.1016/j.jaim.2024.100896
Anjali Punia , Sameeran Chate , Basavaraj R. Tubaki , Nagula Himaja
{"title":"Efficacy of whole system ayurveda management protocol in major depressive disorder- A randomized controlled clinical trial","authors":"Anjali Punia ,&nbsp;Sameeran Chate ,&nbsp;Basavaraj R. Tubaki ,&nbsp;Nagula Himaja","doi":"10.1016/j.jaim.2024.100896","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Major Depressive Disorder (MDD) is one of the common depressive disorder. MDD has high comorbidity and has greater implications on quality of life. Whole system Ayurveda management protocol <em>(WSAP)</em> is explored for it's possible role in management of MDD.</p></div><div><h3>Objective</h3><p>To evaluate the efficacy of Whole system Ayurveda management protocol on Major Depressive Disorder.</p></div><div><h3>Material and Methods</h3><p>Study was a randomized controlled trial. Total 50 patients of MDD meeting the DSM V criteria, age group 20–70 years of either sex participated in the study. They were randomly divided into two groups, control group received Escitalopram 10 mg twice a day and Ayurveda group was on WSAP. Interventions were for 60 days. Assessments were done through various clinical parameters like Hamilton Depression Rating Scale (HDRS), Hamilton Anxiety Rating Scale (HARS), Brief psychiatric rating scale (BPRS), Pittsburgh Sleep Quality Index (PSQI), WHO Quality of Life- BREF (WHOQOL-BREF), Clinical Global Improvement scale (CGI), UKU Side effect scale. Assessments during intervention was on every 15th day.</p></div><div><h3>Results</h3><p>Study showed that Ayurveda group produced significant outcome improvement compared to control group in HDRS (p = 0.01), HARS (p = 0.03), PSQI (p = 0.03), WHOQOL-Bref (p &lt; 0.001) and UKU side effect scale (p = 0.02). Both the group showed improvements in all the parameters except in WHOQOL-Bref where Ayurveda group only showed improvements (p &lt; 0.001). Effect size showed large effect in WHOQOL-Bref. Mild side effects were reported in control group and none in Ayurveda group.</p></div><div><h3>Conclusion</h3><p><em>WSAP was</em> effective in management of MDD and had better side effect profile. Further studies needed.</p></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 2","pages":"Article 100896"},"PeriodicalIF":1.9000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0975947624000111/pdfft?md5=9930dc45b32d0009e6d09c91cfd6bccc&pid=1-s2.0-S0975947624000111-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ayurveda and Integrative Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0975947624000111","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Major Depressive Disorder (MDD) is one of the common depressive disorder. MDD has high comorbidity and has greater implications on quality of life. Whole system Ayurveda management protocol (WSAP) is explored for it's possible role in management of MDD.

Objective

To evaluate the efficacy of Whole system Ayurveda management protocol on Major Depressive Disorder.

Material and Methods

Study was a randomized controlled trial. Total 50 patients of MDD meeting the DSM V criteria, age group 20–70 years of either sex participated in the study. They were randomly divided into two groups, control group received Escitalopram 10 mg twice a day and Ayurveda group was on WSAP. Interventions were for 60 days. Assessments were done through various clinical parameters like Hamilton Depression Rating Scale (HDRS), Hamilton Anxiety Rating Scale (HARS), Brief psychiatric rating scale (BPRS), Pittsburgh Sleep Quality Index (PSQI), WHO Quality of Life- BREF (WHOQOL-BREF), Clinical Global Improvement scale (CGI), UKU Side effect scale. Assessments during intervention was on every 15th day.

Results

Study showed that Ayurveda group produced significant outcome improvement compared to control group in HDRS (p = 0.01), HARS (p = 0.03), PSQI (p = 0.03), WHOQOL-Bref (p < 0.001) and UKU side effect scale (p = 0.02). Both the group showed improvements in all the parameters except in WHOQOL-Bref where Ayurveda group only showed improvements (p < 0.001). Effect size showed large effect in WHOQOL-Bref. Mild side effects were reported in control group and none in Ayurveda group.

Conclusion

WSAP was effective in management of MDD and had better side effect profile. Further studies needed.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
阿育吠陀全系统管理方案对重度抑郁症的疗效--随机对照临床试验
背景重度抑郁症(MDD)是常见的抑郁症之一。重度抑郁症的合并症较高,对生活质量的影响也较大。研究探索了全系统阿育吠陀管理方案(WSAP)在管理 MDD 方面可能发挥的作用。目的 评估全系统阿育吠陀管理方案对重度抑郁症的疗效。共有 50 名符合 DSM V 标准、年龄在 20-70 岁之间的重度抑郁症患者参加了研究。他们被随机分为两组,对照组服用艾司西酞普兰 10 毫克,每天两次,阿育吠陀组服用 WSAP。干预期为 60 天。通过各种临床参数进行评估,如汉密尔顿抑郁评定量表(HDRS)、汉密尔顿焦虑评定量表(HARS)、简明精神病评定量表(BPRS)、匹兹堡睡眠质量指数(PSQI)、世界卫生组织生活质量标准(WHOQOL-BREF)、临床总体改善量表(CGI)、UKU副作用量表。研究结果表明,与对照组相比,阿育吠陀组在 HDRS(p = 0.01)、HARS(p = 0.03)、PSQI(p = 0.03)、WHOQOL-BREF(p < 0.001)和 UKU 副作用量表(p = 0.02)方面均有显著改善。除阿育吠陀组在 WHOQOL-Bref 方面有所改善(p < 0.001)外,两组在所有参数方面均有所改善。效应大小显示,WHOQOL-Bref 的效应较大。对照组有轻微的副作用,而阿育吠陀组没有副作用。需要进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Ayurveda and Integrative Medicine
Journal of Ayurveda and Integrative Medicine INTEGRATIVE & COMPLEMENTARY MEDICINE-
CiteScore
4.70
自引率
12.50%
发文量
136
审稿时长
30 weeks
期刊最新文献
Oral administration of osimertinib mesylate induced multiple peripheral neuropathy of a non-small-cell lung cancer patient and treated with traditional Chinese medicine - A case report Efficacy of standalone personalized Ayurveda management in moderating functional index, inflammatory markers & radiological progression in Ankylosing Spondylitis with 12 years follow up – A case report Prakriti and genetic profiling in Duchenne/Becker muscular dystrophy: An Ayurgenomic appraisal towards personalized care Breaking silos in healthcare: A futuristic vision for Viksit Bharat
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1